Publications by authors named "I Gonzalez-Alvaro"
Article Synopsis
- * Researchers genotyped 552 SNPs in genes related to bone health in 268 patients, using data from the PEARL study, and analyzed their connection to BMD using linear regression.
- * Significant associations were found between specific SNPs in the RANK and OPG genes with clinical severity and BMD; one SNP (rs1805034) was highlighted as a potential biomarker for severity in rheumatoid arthritis patients.
Article Synopsis
- * Key findings indicated that certain genetic variations in the TYK2 and VIP genes were linked to a reduced severity of the disease, while variations in TLR7 and OAS1 were associated with increased severity.
- * The research suggests that these genetic markers could help identify individuals at greater risk for severe COVID-19 outcomes.
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by severe organ damage and lacking curative treatment. While various immune cell types, especially dysfunctional B and T cells and neutrophils, have been related with disease pathogenesis, limited research has focused on the role of monocytes in SLE. Increased DNA extracellular traps, apoptosis and necrosis have been related to lupus pathogenesis.
View Article and Find Full Text PDFBackground: Early diagnosis and treatment of Systemic lupus erythematosus (SLE) and Systemic sclerosis (SSc) present significant challenges for clinicians. Although various studies have observed changes in serum levels of selectins between healthy donors and patients with autoimmune diseases, including SLE and SSc, their potential as biomarkers has not been thoroughly explored. We aimed to investigate serum profiles of PSGL-1 (sPSGL-1), ADAM8 (sADAM8) and P-, E- and L-selectins (sP-, sE- and sL-selectins) in defined SLE and SSc patient cohorts to identify disease-associated molecular patterns.
View Article and Find Full Text PDFArticle Synopsis
- This study analyzed the effectiveness and safety of COVID-19 vaccines in rheumatoid arthritis (RA) patients undergoing immunomodulatory treatments, using data from a single center between December 2020 and October 2021.
- It included 118 patients, predominantly women aged around 65, with most achieving good immune responses and a high completion rate of vaccinations.
- The findings indicated that while 88.1% had adequate antibody responses and mild adverse events were noted in 19.5% of patients, 18.6% still contracted COVID-19 post-vaccination, particularly influenced by factors such as previous infections and vaccine type.